Objective: To compare effects of Atorvastatin (40mg/80mg) and 0.1% Betamethasone Valerate on progress of psoriasis with cardiovascular complications.
Methodology: This study was comparative interventional randomized clinical trial conducted in Pharmacology Department of Basic Medical Sciences Institute, Jinnah Postgraduate Medical Center (JPMC), with the collaboration of Dermatology department of JPMC, Karachi. The study period was from June 2013 to June 2016. A total of 225 patients were divided into group A, B and C. Post treatment effects of drugs were evaluated by different parameters (Psoriasis Area and Severity Index (PASI), High Sensitivity C-Reactive Protein (hsCRP), Lipid profile, Liver Function Test (LFT) Creatine Phosphokinase (CPK)). The quality of life was evaluated in those patients by Dermatological Life Quality Index(DLQI).
Results: The mean percentage change of PASI and hsCRP showed highly significant changes at twelve and twenty weeks. Before and after the treatment mean Lipid profile and DLQI also showed significant changed. LFT and adverse event had non-significant change at the end of treatment.
Conclusion: Atorvastatin had remarkable results on psoriasis disease severity and cardiovascular complication were same as standard therapy 0.1% Betamethasone Valerate. When the combination of drugs was used, more significant results were seen as compared to single therapy.
Key words: Atorvastatin, 0.1% Betamethasone Valerate, Psoriasis Severity and Cardiovascular complication.
|
